Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Staging Systems to Predict Metastatic Cutaneous Squamous Cell Carcinoma

Staging Systems to Predict Metastatic Cutaneous Squamous Cell Carcinoma Opinion EDITORIAL Staging Systems to Predict Metastatic Cutaneous Squamous Cell Carcinoma Unsatisfactory for Clinical Use, but Some Less So? Ivo Abraham, PhD; Clara Curiel-Lewandrowski, MD siderable uncertainty. Correct classification rates were mod- Disease staging systems play 2 critical roles in oncology. In the first instance, these systems summarize the extent of a pa- est at best and were weakened by significant uncertainty as tient’s cancer at the time of diagnosis and disease progression, well. The rates also indicated that about one-quarter to one- by including information on the tumor characteristics at the pri- third of patients were classified incorrectly—hardly an encour- mary site (eg, location, size, histologic features, etc) as well as aging finding when the issue is whether clinicians can advise locoregional (lymph node involvement) and distant meta- patients, reasonably so, as to whether they will or will not de- static state. Second, clinicians use these systems to evaluate velop metastatic disease. treatment options, assess prognosis, and plan their patients’ The Breuninger and BWH staging systems seemed to differ- care. Ideally, staging systems should have strong prognostic entiate from the 2 AJCC staging systems in terms of the C-index value so that clinicians can inform patients, with a http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Dermatology American Medical Association

Staging Systems to Predict Metastatic Cutaneous Squamous Cell Carcinoma

Abraham, Ivo; Curiel-Lewandrowski, Clara
JAMA Dermatology , Volume 154 (12) – Dec 7, 2018
Download PDF
2 pages

Loading next page...
 
/lp/american-medical-association/staging-systems-to-predict-metastatic-cutaneous-squamous-cell-QHGJAXQlIh

References (12)

Publisher
American Medical Association
Copyright
Copyright 2018 American Medical Association. All Rights Reserved.
ISSN
2168-6068
eISSN
2168-6084
DOI
10.1001/jamadermatol.2018.3940
Publisher site
See Article on Publisher Site

Abstract

Opinion EDITORIAL Staging Systems to Predict Metastatic Cutaneous Squamous Cell Carcinoma Unsatisfactory for Clinical Use, but Some Less So? Ivo Abraham, PhD; Clara Curiel-Lewandrowski, MD siderable uncertainty. Correct classification rates were mod- Disease staging systems play 2 critical roles in oncology. In the first instance, these systems summarize the extent of a pa- est at best and were weakened by significant uncertainty as tient’s cancer at the time of diagnosis and disease progression, well. The rates also indicated that about one-quarter to one- by including information on the tumor characteristics at the pri- third of patients were classified incorrectly—hardly an encour- mary site (eg, location, size, histologic features, etc) as well as aging finding when the issue is whether clinicians can advise locoregional (lymph node involvement) and distant meta- patients, reasonably so, as to whether they will or will not de- static state. Second, clinicians use these systems to evaluate velop metastatic disease. treatment options, assess prognosis, and plan their patients’ The Breuninger and BWH staging systems seemed to differ- care. Ideally, staging systems should have strong prognostic entiate from the 2 AJCC staging systems in terms of the C-index value so that clinicians can inform patients, with a

Journal

JAMA Dermatology – American Medical Association

Published: Dec 7, 2018

There are no references for this article.